TY - JOUR
T1 - Long-Term Technical Performance of the Osypka QT-5, javax.xml.bind.JAXBElement@731a9fda, Ventricular Pacemaker Lead
AU - Semmler, Georg
AU - Barbieri, Fabian
AU - Thudt, Karin
AU - Vock, Paul
AU - Mörtl, Deddo
AU - Mayr, Harald
AU - Wollmann, Christian Georg
AU - Adukauskaite, Agne
AU - Pfeifer, Bernhard Erich
AU - Pfeifer, Bernhard Erich
AU - Senoner, Thomas
AU - Dichtl, Wolfgang
PY - 2021
Y1 - 2021
N2 - Background: Lead-associated complications and technical issues in patients with cardiac
implantable electronic devices are common but underreported in the literature. Methods: All patients
undergoing implantation of the Osypka QT-5® ventricular lead at the University Clinic St. Pölten
between 1 January 2006 and 31 December 2012 were retrospectively analyzed (n = 211). Clinical
data including pacemaker follow-up examinations and the need for lead revisions were assessed.
KaplanMeier analysis to estimate the rate of lead dysfunction during long-term follow-up was
conducted. Results: Patients were followed for a median of 5.2 years (interquartile range (IQR)
2.08.7). R-wave sensing properties at implantation, compared to last follow-up, remained basically
unchanged: 9.9 mV (IQR 6.813.4) and 9.6 mV (IQR 5.612.0), respectively). Ventricular pacing
threshold significantly increased between implantation (0.5 V at 0.4 ms; IQR 0.50.8) and the first
follow-up visit (1.0 V at 0.4 ms; IQR 0.81.3; p < 0.001) and this increase persisted throughout to
the last check-up (0.9 V at 0.4 ms; IQR 0.81.2). Impedance significantly declined from 1142 Ω
(IQR 9551285) at implantation to 814 Ω (IQR 701949; p < 0.001) at the first check-up, followed by a
further decrease to 450 Ω (IQR 289652; p < 0.001) at the last check-up. Overall, the Osypka QT-5®
ventricular lead was replaced in 36 patients (17.1%). Conclusions: This report shows an unexpected
high rate of technical issues of the Osypka QT-5® ventricular lead during long-term follow-up.
AB - Background: Lead-associated complications and technical issues in patients with cardiac
implantable electronic devices are common but underreported in the literature. Methods: All patients
undergoing implantation of the Osypka QT-5® ventricular lead at the University Clinic St. Pölten
between 1 January 2006 and 31 December 2012 were retrospectively analyzed (n = 211). Clinical
data including pacemaker follow-up examinations and the need for lead revisions were assessed.
KaplanMeier analysis to estimate the rate of lead dysfunction during long-term follow-up was
conducted. Results: Patients were followed for a median of 5.2 years (interquartile range (IQR)
2.08.7). R-wave sensing properties at implantation, compared to last follow-up, remained basically
unchanged: 9.9 mV (IQR 6.813.4) and 9.6 mV (IQR 5.612.0), respectively). Ventricular pacing
threshold significantly increased between implantation (0.5 V at 0.4 ms; IQR 0.50.8) and the first
follow-up visit (1.0 V at 0.4 ms; IQR 0.81.3; p < 0.001) and this increase persisted throughout to
the last check-up (0.9 V at 0.4 ms; IQR 0.81.2). Impedance significantly declined from 1142 Ω
(IQR 9551285) at implantation to 814 Ω (IQR 701949; p < 0.001) at the first check-up, followed by a
further decrease to 450 Ω (IQR 289652; p < 0.001) at the last check-up. Overall, the Osypka QT-5®
ventricular lead was replaced in 36 patients (17.1%). Conclusions: This report shows an unexpected
high rate of technical issues of the Osypka QT-5® ventricular lead during long-term follow-up.
KW - pacemaker malfunction; impedance decline; reoperation; lead replacement
KW - pacemaker malfunction; impedance decline; reoperation; lead replacement
U2 - 10.3390/jcm10040639
DO - 10.3390/jcm10040639
M3 - Article
SP - 1
EP - 9
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 639
ER -